NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Immunomedics, Inc. (NASDAQ: IMMU)
Class Period: February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, Immunomedics, Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance
with FDA requirements; (ii) the Company’s Quality Control Unit did not possess the authority to investigate and correct
critical FDA violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a
Februar 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the
backdating records and manipulation of bioburden samples; (iv) the Company’s Chemistry, Manufacturing and Control data submitted in
connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company’s
public statements were materially false and misleading at all relevant times.
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
Ferroglobe PLC (NASDAQ: GSM)
Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
Join the action: https://www.zlk.com/pslra-1/ferroglobe-plc-loss-form?wire=3
About the lawsuit: Ferroglobe PLC allegedly made materially false and/or misleading statements and/or failed to disclose: (1)
there was excess supply of the Company’s products; (2) demand for the Company’s products was declining; (3) as a result, the
pricing of the Company’s products would be materially impacted; and (4) as a result of the foregoing, Defendants’ positive
statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable
basis.
To learn more about the Ferroglobe PLC class action contact jlevi@levikorsinsky.com.
Tyme Technologies, Inc. (NASDAQCM: TYME)
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3
About the lawsuit: During the class period, Tyme Technologies, Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of
SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial
for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in
the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.
To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com.
General Electric Company (NYSE: GE)
Class Period: December 27, 2017 - October 29, 2018
Lead Plaintiff Deadline: April 2, 2019
Join the action: https://www.zlk.com/pslra-1/general-electric-company-loss-form?wire=3
About the lawsuit: Throughout the class period, General Electric Company allegedly made materially false and/or misleading
statements and/or failed to disclose: (i) the design and technology of GE Power’s flagship gas turbines were structurally flawed as
they were plagued with an oxidation problem that caused the blades in the H-Class gas turbines to fail; (ii) GE Power’s goodwill
was materially overstated, in large part because of such structural issues; (iii) the Company lacked adequate internal and
financial controls; and (iv) as a result of the foregoing, Defendant’s public statements were materially false and/or misleading
and/or lacked a reasonable basis.
To learn more about the General Electric Company class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
